

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS	23	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	24	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	25	MAR 03	FRANCEPAT now available on STN
NEWS	EXPRESS		MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	INTER		General Internet Information
NEWS	LOGIN		Welcome Banner and News Items
NEWS	PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:55:11 ON 09 MAR 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis, COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 16:55:39 ON 09 MAR 2004

FILE 'USPATFULL' ENTERED AT 16:55:39 ON 09 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:55:39 ON 09 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:55:39 ON 09 MAR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:55:39 ON 09 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 16:55:39 ON 09 MAR 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 16:55:39 ON 09 MAR 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 16:55:39 ON 09 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s Islet Neogenesis Associated Protein or INGAP
L1 2299 ISLET NEOGENESIS ASSOCIATED PROTEIN OR INGAP

=> s l1 and nucleotide
L2 52 L1 AND NUCLEOTIDE

=> s l2 and encoding protein
5 FILES SEARCHED...
L3 0 L2 AND ENCODING PROTEIN

=> ss l2 and primers
L4 36 L2 AND PRIMERS

=> s l4 and recombinant construct
L5 3 L4 AND RECOMBINANT CONSTRUCT

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 3 USPATFULL on STN
TI High level of expression of **ingap** in bacterial and eukaryotic cells
AB Removal of the **nucleotide** sequence encoding the signal peptide from the **INGAP** coding sequence allows cultured cells to express substantial amounts of **INGAP** activity. Previous attempts have provided only low yields of **INGAP**, possibly because the signal sequence of **INGAP** is toxic to the cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:108255 USPATFULL

TITLE: High level of expression of **ingap** in bacterial and eukaryotic cells

INVENTOR(S): Vinik, Aaron I., Norfolk, VA, United States
Pittenger, Gary L., Virginia Beach, VA, United States
Rafaeloff-Phail, Ronit, Chesapeake, VA, United States
Barlow, Scott W., Norfolk, VA, United States

PATENT ASSIGNEE(S): Eastern Virginia Medical School of the Medical College of Hampton Roads, Norfolk, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804421		19980908
APPLICATION INFO.:	US 1997-909725		19970812 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-741096, filed on 30 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	848		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 3 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Expressing high levels of **INGAP** using recombinant constructs - comprising sequence encoding **INGAP** but with sequence encoding signal peptide removed, useful for **INGAP** production e.g. to treat diabetes

AN AAV30283 DNA DGENE

AB The **primers** AAV30282 and AAV30283 were used to exclude the **INGAP** 5'UTR and signal peptide sequence from a **recombinant construct** for expressing **INGAP** activity containing a **nucleotide** sequence encoding amino acids 27-175 of **INGAP** operably linked to a transcription initiation site and a translational initiation site. The construct can be used to produce biologically active **INGAP**, by culturing the transformed host cells. **INGAP** is found within a pancreatic extract called Iltropin and is known to be responsible for stimulating cell regeneration of the pancreatic islets of Langerhans. The **INGAP** produced is useful in treatments to regenerate the islets of Langerhans to prevent or ameliorate the symptoms of diabetes mellitus. Previous methods have produced only low yields of **INGAP**, possibly because the **INGAP** signal sequence is toxic to bacteria.

ACCESSION NUMBER: AAV30283 DNA DGENE

TITLE: Expressing high levels of **INGAP** using recombinant constructs - comprising sequence encoding **INGAP** but with sequence encoding signal peptide removed, useful for **INGAP** production e.g. to treat diabetes

INVENTOR: Barlow S W; Pittenger G I; Rafaeloff R; Vinik A I

PATENT ASSIGNEE: (EVIR-N) EASTERN VIRGINIA MEDICAL SCHOOL.

PATENT INFO: WO 9818913 A1 19980507 22p

APPLICATION INFO: WO 1997-US19415 19971030

PRIORITY INFO: US 1996-741096 19961030

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-272209 [24]

DESCRIPTION: **INGAP** 3' primer.

L5 ANSWER 3 OF 3 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Expressing high levels of **INGAP** using recombinant constructs -

comprising sequence encoding **INGAP** but with sequence encoding signal peptide removed, useful for **INGAP** production e.g. to treat diabetes

AN AAV30282 DNA DGENE

AB The **primers** AAV30282 and AAV30283 were used to exclude the **INGAP** 5'UTR and signal peptide sequence from a **recombinant construct** for expressing **INGAP** activity containing a **nucleotide** sequence encoding amino acids 27-175 of **INGAP** operably linked to a transcription initiation site and a translational initiation site. The construct can be used to produce biologically active **INGAP**, by culturing the transformed host cells. **INGAP** is found within a pancreatic extract called Iltotropin and is known to be responsible for stimulating cell regeneration of the pancreatic islets of Langerhans. The **INGAP** produced is useful in treatments to regenerate the islets of Langerhans to prevent or ameliorate the symptoms of diabetes mellitus. Previous methods have produced only low yields of **INGAP**, possibly because the **INGAP** signal sequence is toxic to bacteria.

ACCESSION NUMBER: AAV30282 DNA DGENE

TITLE: Expressing high levels of **INGAP** using recombinant constructs - comprising sequence encoding **INGAP** but with sequence encoding signal peptide removed, useful for **INGAP** production e.g. to treat diabetes

INVENTOR: Barlow S W; Pittenger G I; Rafaeloff R; Vinik A I

PATENT ASSIGNEE: (EVIR-N)EASTERN VIRGINIA MEDICAL SCHOOL.

PATENT INFO: WO 9818913 A1 19980507 22p

APPLICATION INFO: WO 1997-US19415 19971030

PRIORITY INFO: US 1996-741096 19961030

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-272209 [24]

DESCRIPTION: **INGAP** 5' primer.

=> d his

(FILE 'HOME' ENTERED AT 16:55:11 ON 09 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 16:55:39 ON 09 MAR 2004

L1 2299 S ISLET NEOGENESIS ASSOCIATED PROTEIN OR INGAP

L2 52 S L1 AND NUCLEOTIDE

L3 0 S L2 AND ENCODING PROTEIN

L4 36 SS L2 AND PRIMERS

L5 3 S L4 AND RECOMBINANT CONSTRUCT

=> d l4 ti abs ibib 1-20

L4 ANSWER 1 OF 36 USPATFULL on STN

TI Gene expression in bladder tumors

AB Methods for analyzing tumor cells, particularly bladder tumor cells employ gene expression analysis of samples. Gene expression patterns are formed and compared to reference patterns. Alternatively gene expression patterns are manipulated to exclude genes which are expressed in contaminating cell populations. Another alternative employs subtraction of the expression of genes which are expressed in contaminating cell types. These methods provide improved accuracy as well as alternative basis for analysis from diagnostic and prognostic tools currently available.

ACCESSION NUMBER: 2004:50778 USPATFULL

TITLE: Gene expression in bladder tumors

INVENTOR(S): Orntoft, Torben F., Aabyhoj, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038207	A1	20040226
APPLICATION INFO.:	US 2001-951968	A1	20010914 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-510643, filed on 22 Feb 2000, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Page(s)		
LINE COUNT:	28561		

L4 ANSWER 2 OF 36 USPATFULL on STN
 TI Modified transferrin fusion proteins
 AB Modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:31195 USPATFULL
 TITLE: Modified transferrin fusion proteins
 INVENTOR(S): Prior, Christopher P., Philadelphia, PA, UNITED STATES
 PATENT ASSIGNEE(S): BioRexis Pharmaceutical Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004023334	A1	20040205
APPLICATION INFO.:	US 2002-231494	A1	20020830 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315745P	20010830 (60)
	US 2001-334059P	20011130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	15780	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 36 USPATFULL on STN
 TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
 AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:318756 USPATFULL
 TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
 INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 16963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 36 USPATFULL on STN
TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306402 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215836	A1	20031120
APPLICATION INFO.:	US 2003-345236	A1	20030116 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,

ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 17572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 36 USPATFULL on STN
TI Assay for the detection of factors that modulate the expression of
INGAP
AB A reporter construct contains mammalian **INGAP** 5'-regulatory region or a fragment thereof, a minimal promoter element from mammalian **INGAP** or a heterologous promoter, and a reporter gene. The reporter construct can be used to screen for agents which alone or in combination up-regulate or down-regulate reporter gene expression. Alternatively, the reporter construct can be used to screen for agents that bind to the hamster **INGAP** 5'-regulatory region or a fragment thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:294286 USPATFULL
TITLE: Assay for the detection of factors that modulate the expression of **INGAP**
INVENTOR(S): Taylor-Fishwick, David A., Norfolk, VA, UNITED STATES
Vinik, Aaron I., Norfolk, VA, UNITED STATES
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, UNITED STATES, 45224 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207301	A1	20031106
APPLICATION INFO.:	US 2003-339767	A1	20030109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-388315P	20020614 (60)
	US 2002-361073P	20020301 (60)
	US 2002-346898P	20020111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI, OH, 45224	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	2709	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 36 USPATFULL on STN
TI Cyanine dye compounds and labeling methods
AB A novel cyanine dye having the formula ##STR1##

is useful for labeling biological and nonbiological molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:190696 USPATFULL
TITLE: Cyanine dye compounds and labeling methods
INVENTOR(S): Narayanan, Narasimhachari, Lincoln, NE, United States
PATENT ASSIGNEE(S): Li-Cor, Inc., Lincoln, NE, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6593148 B1 20030715
 APPLICATION INFO.: US 2000-520770 20000307 (9)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-143153, filed on 20 Aug 1998, now abandoned Division of Ser. No. US 1995-500691, filed on 11 Jul 1995, now patented, Pat. No. US 6086737 Continuation-in-part of Ser. No. US 1994-204627, filed on 1 Mar 1994, now patented, Pat. No. US 5571388
 DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Ceperley, Mary E.
 LEGAL REPRESENTATIVE: Rothwell, Figg, Ernst & Manbeck
 NUMBER OF CLAIMS: 2
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
 LINE COUNT: 1025
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 36 USPATFULL on STN

TI Full-length serine protein kinase in brain and pancreas
 AB The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine, etc. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, especially relating to brain and pancreas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:140430 USPATFULL
 TITLE: Full-length serine protein kinase in brain and pancreas
 INVENTOR(S): Shu, Youmin, Potomac, MD, UNITED STATES
 Fan, Wufang, Germantown, MD, UNITED STATES
 Kovacs, Karl F., Rockville, MD, UNITED STATES
 Zidanic, Michael, Derwood, MD, UNITED STATES
 Jay, Gilbert, North Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096271	A1	20030522
APPLICATION INFO.:	US 2002-195071	A1	20020715 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-930181, filed on 16 Aug 2001, GRANTED, Pat. No. US 6455292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ORIGENE TECHNOLOGIES, INCORPORATED, 6 TAFT COURT, SUITE 100, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	2764		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 36 USPATFULL on STN

TI Full-length serine protein kinase in brain and pancreas
 AB The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine, etc. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as

molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, especially relating to brain and pancreas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133951 USPATFULL
 TITLE: Full-length serine protein kinase in brain and pancreas
 INVENTOR(S): Shu, Youmin, Potomac, MD, UNITED STATES
 Fan, Wufang, Germantown, MD, UNITED STATES
 Kovacs, Karl F., Rockville, MD, UNITED STATES
 Zidanic, Michael, Derwood, MD, UNITED STATES
 Jay, Gilbert, North Bethesda, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092036	A1	20030515
APPLICATION INFO.:	US 2002-195072	A1	20020715 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-930181, filed on '16 Aug 2001, GRANTED, Pat. No. US 6455292		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ORIGENE TECHNOLOGIES, INCORPORATED, 6 TAFT COURT, SUITE 100, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	2773		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 36 USPATFULL on STN

TI Full-length serine protein kinase in brain and pancreas
 AB The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to diseases and conditions, especially relating to brain and pancreas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:246571 USPATFULL
 TITLE: Full-length serine protein kinase in brain and pancreas
 INVENTOR(S): Shu, Youmin, Potomac, MD, United States
 Fan, Wufang, Germantown, MD, United States
 Kovacs, Karl F., Rockville, MD, United States
 Zidanic, Michael, Derwood, MD, United States
 Jay, Gilbert, North Bethesda, MD, United States
 PATENT ASSIGNEE(S): OriGene Technologies, Inc, Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455292	B1	20020924
APPLICATION INFO.:	US 2001-930181		20010816 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Murthy, Ponnathapuachuta		
ASSISTANT EXAMINER:	Ramirez, Delia		
LEGAL REPRESENTATIVE:	Lebovitz, Richard M.		
NUMBER OF CLAIMS:	6		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 36 USPATFULL on STN

TI Gene markers for chronic mucosal injury

AB The invention provides gene markers for chronic mucosal injury and ulcerative colitis. Expression products of the REG gene family can be used to detect the presence of chronic mucosal injury in a body sample of a human. The expression products of a gene represented by a Hs.111244 polynucleotide can be used to detect ulcerative colitis in a body sample of a human. Further, these markers can be used to differentiate humans with chronic mucosal injury from humans with common acute inflammatory colon disorder, common non-inflammatory benign colon disorder, and healthy colons. The degree of injury to the colon from chronic mucosal injury can be determined and the efficacy of therapy for chronic mucosal injury can be monitored. A method of screening compounds for anti-chronic mucosal injury and anti-ulcerative activity is also provided by these gene markers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:54606 USPATFULL
TITLE: Gene markers for chronic mucosal injury
INVENTOR(S): Dieckgraefe, Brian K., St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002031767	A1	20020314
APPLICATION INFO.:	US 2000-739262	A1	20001219 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-146969, filed on 4 Sep 1998, GRANTED, Pat. No. US 6228585		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001		
NUMBER OF CLAIMS:	76		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	870		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 36 USPATFULL on STN

TI Gene markers for chronic mucosal injury

AB The invention provides gene markers for chronic mucosal injury and ulcerative colitis. Expression products of the REG gene family can be used to detect the presence of chronic mucosal injury in a body sample of a human. The expression products of a gene represented by a Hs.111244 polynucleotide can be used to detect ulcerative colitis in a body sample of a human. Further, these markers can be used to differentiate humans with chronic mucosal injury from humans with common acute inflammatory colon disorder, common non-inflammatory benign colon disorder, and healthy colons. The degree of injury to the colon from chronic mucosal injury can be determined and the efficacy of therapy for chronic mucosal injury can be monitored. A method of screening compounds for anti-chronic mucosal injury and anti-ulcerative activity is also provided by these gene markers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:67396 USPATFULL
TITLE: Gene markers for chronic mucosal injury
INVENTOR(S): Dieckgraefe, Brian K., St. Louis, MO, United States
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228585	B1	20010508
APPLICATION INFO.:	US 1998-146969		19980904 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Arthur, Lisa B.		
LEGAL REPRESENTATIVE:	Banner & Witcoff LTD		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	531		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 36 USPATFULL on STN

TI **Ingap** protein involved in pancreatic islet neogenesis

AB Cellophane wrapping (CW) of hamster pancreas induces proliferation of duct epithelial cells followed by endocrine cell differentiation and islet neogenesis. Using the mRNA differential display technique a cDNA clone expressed in cellophane wrapped but not in control pancreata was identified. Using this cDNA as a probe, a cDNA library was screened and a gene not previously described was identified and named **INGAP**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:147253 USPATFULL

TITLE: **Ingap** protein involved in pancreatic islet neogenesis

INVENTOR(S): Vinik, Aaron I., Norfolk, VA, United States
Pittenger, Gary L., Virginia Beach, VA, United States
Rafaeloff, Ronit, Chesapeake, VA, United States
Rosenberg, Lawrence, Montreal, Canada
Duguid, William P., Montreal, Canada

PATENT ASSIGNEE(S): McGill University, Canada (non-U.S. corporation)
Eastern Virginia Medical School of the Medicine College of Hampton Roads, Norfolk, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840531		19981124
APPLICATION INFO.:	US 1996-709662		19960909 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-401530, filed on 22 Feb 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Grimes, Eric		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Banner & Witocoff, Ltd		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	969		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 36 USPATFULL on STN

TI **Ingap** protein involved in pancreatic islet neogenesis

AB Cellophane wrapping (CW) of hamster pancreas induces proliferation of duct epithelial cells followed by endocrine cell differentiation and islet neogenesis. Using the mRNA differential display technique a cDNA clone expressed in cellophane wrapped but not in control pancreata was identified. Using this cDNA as a probe, a cDNA library was screened and a gene not previously described was identified and named **INGAP**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:139021 USPATFULL
TITLE: **Ingap** protein involved in pancreatic islet
neogenesis
INVENTOR(S): Vinik, Aaron I., Norfolk, VA, United States
Pittenger, Gary L., Virginia Beach, VA, United States
Rafaeloff, Ronit, Norfolk, VA, United States
Rosenberg, Lawrence, Montreal, Canada
Duguid, William P., Montreal, Canada
PATENT ASSIGNEE(S): Eastern Virginia Medical School of the Medical College
of Hampton Roads, Norfolk, VA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834590		19981110
APPLICATION INFO.:	US 1995-401530		19950222 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	941		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 36 USPATFULL on STN

TI High level of expression of **ingap** in bacterial and eukaryotic
cells
AB Removal of the **nucleotide** sequence encoding the signal peptide
from the **INGAP** coding sequence allows cultured cells to
express substantial amounts of **INGAP** activity. Previous
attempts have provided only low yields of **INGAP**, possibly
because the signal sequence of **INGAP** is toxic to the cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:108255 USPATFULL
TITLE: High level of expression of **ingap** in
bacterial and eukaryotic cells
INVENTOR(S): Vinik, Aaron I., Norfolk, VA, United States
Pittenger, Gary L., Virginia Beach, VA, United States
Rafaeloff-Phail, Ronit, Chesapeake, VA, United States
Barlow, Scott W., Norfolk, VA, United States
PATENT ASSIGNEE(S): Eastern Virginia Medical School of the Medical College
of Hampton Roads, Norfolk, VA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804421		19980908
APPLICATION INFO.:	US 1997-909725		19970812 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-741096, filed on 30 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Longton, Enrique D.		
LEGAL REPRESENTATIVE:	Banner & Witcoff, Ltd.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 36 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New isolated **INGAP** nucleic acid, useful for diagnosing and
treating disorders associated with reduced islet cell function and/or
aberrant expression or activity of **INGAP**, such as type II
diabetes mellitus.
AN ACF05867 DNA DGENE
AB The present sequence is that of PCR primer INGEN 13_5, corresponding to
nucleotides 5463-5485 of the hamster islet neogenesis gene associated
protein (**INGAP**) gene. It is one of a set of **primers**
(see ACF05852-71) used to generate PCR fragments of the **INGAP**
gene, which were subsequently sequenced to determine the
nucleotide sequence (see ACF05851) of the **INGAP** 5'
regulatory region, the introns, the intron/exon junctions, and the 3'
polyadenylation region. The 5' regulatory region of the **INGAP**
gene is susceptible to modulation by many known transcription factors,
and is used in claimed screening assays to identify agents capable of
modulating **INGAP** gene expression. These modulating agents have
potential as therapeutic agents for treating type 1 and type 2 diabetes
mellitus, endocrine and non-endocrine hypoplasia, hypertrophy, adenoma,
neoplasia and nesidioblastosis
ACCESSION NUMBER: ACF05867 DNA DGENE
TITLE: New isolated **INGAP** nucleic acid, useful for
diagnosing and treating disorders associated with reduced
islet cell function and/or aberrant expression or activity
of **INGAP**, such as type II diabetes mellitus.
INVENTOR: Taylor-Fishwick D; Vinik A I
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2003060096 A2 20030724 118p
APPLICATION INFO: WO 2003-US707 20030110
PRIORITY INFO: US 2002-346898P 20020111
US 2002-361073P 20020301
US 2002-388315P 20020614
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-598524 [56]
DESCRIPTION: Hamster **INGAP** gene PCR primer INGEN 13_5.

L4 ANSWER 16 OF 36 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New isolated **INGAP** nucleic acid, useful for diagnosing and
treating disorders associated with reduced islet cell function and/or
aberrant expression or activity of **INGAP**, such as type II
diabetes mellitus.
AN ACF05869 DNA DGENE
AB The present sequence is that of PCR primer INGAP1_1R, corresponding to
nucleotides 5957-5976 of the hamster islet neogenesis gene associated
protein (**INGAP**) gene. It is one of a set of **primers**
(see ACF05852-71) used to generate PCR fragments of the **INGAP**
gene, which were subsequently sequenced to determine the
nucleotide sequence (see ACF05851) of the **INGAP** 5'
regulatory region, the introns, the intron/exon junctions, and the 3'
polyadenylation region. The 5' regulatory region of the **INGAP**
gene is susceptible to modulation by many known transcription factors,
and is used in claimed screening assays to identify agents capable of
modulating **INGAP** gene expression. These modulating agents have
potential as therapeutic agents for treating type 1 and type 2 diabetes
mellitus, endocrine and non-endocrine hypoplasia, hypertrophy, adenoma,
neoplasia and nesidioblastosis
ACCESSION NUMBER: ACF05869 DNA DGENE
TITLE: New isolated **INGAP** nucleic acid, useful for
diagnosing and treating disorders associated with reduced

islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.

INVENTOR: Taylor-Fishwick D; Vinik A I
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2003060096 A2 20030724 118p
APPLICATION INFO: WO 2003-US707 20030110
PRIORITY INFO: US 2002-346898P 20020111
US 2002-361073P 20020301
US 2002-388315P 20020614
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-598524 [56]
DESCRIPTION: Hamster **INGAP** gene PCR primer **INGAP1_1R**.

L4 ANSWER 17 OF 36 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.
AN ACF05853 DNA DGENE
AB The present sequence is that of PCR primer **INGEN 19_3**, corresponding to nucleotides 1401-1423 of the hamster islet neogenesis gene associated protein (**INGAP**) gene. It is one of a set of **primers** (see ACF05852-71) used to generate PCR fragments of the **INGAP** gene, which were subsequently sequenced to determine the **nucleotide** sequence (see ACF05851) of the **INGAP 5'** regulatory region, the introns, the intron/exon junctions, and the 3' polyadenylation region. The 5' regulatory region of the **INGAP** gene is susceptible to modulation by many known transcription factors, and is used in claimed screening assays to identify agents capable of modulating **INGAP** gene expression. These modulating agents have potential as therapeutic agents for treating type 1 and type 2 diabetes mellitus, endocrine and non-endocrine hypoplasia, hypertrophy, adenoma, neoplasia and nesidioblastosis

ACCESSION NUMBER: ACF05853 DNA DGENE
TITLE: New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.
INVENTOR: Taylor-Fishwick D; Vinik A I
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2003060096 A2 20030724 118p
APPLICATION INFO: WO 2003-US707 20030110
PRIORITY INFO: US 2002-346898P 20020111
US 2002-361073P 20020301
US 2002-388315P 20020614
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-598524 [56]
DESCRIPTION: Hamster **INGAP** gene PCR primer **INGEN 19_3**.

L4 ANSWER 18 OF 36 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.
AN ACF05859 DNA DGENE
AB The present sequence is that of PCR primer **INGEN 7_3**, corresponding to nucleotides 2666-2689 of the hamster islet neogenesis gene associated protein (**INGAP**) gene. It is one of a set of **primers** (see ACF05852-71) used to generate PCR fragments of the **INGAP** gene, which were subsequently sequenced to determine the **nucleotide** sequence (see ACF05851) of the **INGAP 5'** regulatory region, the introns, the intron/exon junctions, and the 3'

polyadenylation region. The 5' regulatory region of the **INGAP** gene is susceptible to modulation by many known transcription factors, and is used in claimed screening assays to identify agents capable of modulating **INGAP** gene expression. These modulating agents have potential as therapeutic agents for treating type 1 and type 2 diabetes mellitus, endocrine and non-endocrine hypoplasia, hypertrophy, adenoma, neoplasia and nesidioblastosis

ACCESSION NUMBER: ACF05859 DNA DGENE
TITLE: New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.
INVENTOR: Taylor-Fishwick D; Vinik A I
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2003060096 A2 20030724 118p
APPLICATION INFO: WO 2003-US707 20030110
PRIORITY INFO: US 2002-346898P 20020111
US 2002-361073P 20020301
US 2002-388315P 20020614
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-598524 [56]
DESCRIPTION: Hamster **INGAP** gene PCR primer INGEN 7_3.

L4 ANSWER 19 OF 36 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.

AN ACF05868 DNA DGENE

AB The present sequence is that of PCR primer INGAP1_1L, corresponding to nucleotides 3475-3492 of the hamster islet neogenesis gene associated protein (**INGAP**) gene. It is one of a set of **primers** (see ACF05852-71) used to generate PCR fragments of the **INGAP** gene, which were subsequently sequenced to determine the **nucleotide** sequence (see ACF05851) of the **INGAP** 5' regulatory region, the introns, the intron/exon junctions, and the 3' polyadenylation region. The 5' regulatory region of the **INGAP** gene is susceptible to modulation by many known transcription factors, and is used in claimed screening assays to identify agents capable of modulating **INGAP** gene expression. These modulating agents have potential as therapeutic agents for treating type 1 and type 2 diabetes mellitus, endocrine and non-endocrine hypoplasia, hypertrophy, adenoma, neoplasia and nesidioblastosis

ACCESSION NUMBER: ACF05868 DNA DGENE
TITLE: New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.
INVENTOR: Taylor-Fishwick D; Vinik A I
PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.
PATENT INFO: WO 2003060096 A2 20030724 118p
APPLICATION INFO: WO 2003-US707 20030110
PRIORITY INFO: US 2002-346898P 20020111
US 2002-361073P 20020301
US 2002-388315P 20020614
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2003-598524 [56]
DESCRIPTION: Hamster **INGAP** gene PCR primer INGAP1_1L.

L4 ANSWER 20 OF 36 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or

aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.

AN ACF05863 DNA DGENE

AB The present sequence is that of PCR primer INGEN 1_3, corresponding to nucleotides 3475-3501 of the hamster islet neogenesis gene associated protein (**INGAP**) gene. It is one of a set of **primers** (see ACF05852-71) used to generate PCR fragments of the **INGAP** gene, which were subsequently sequenced to determine the **nucleotide** sequence (see ACF05851) of the **INGAP** 5' regulatory region, the introns, the intron/exon junctions, and the 3' polyadenylation region. The 5' regulatory region of the **INGAP** gene is susceptible to modulation by many known transcription factors, and is used in claimed screening assays to identify agents capable of modulating **INGAP** gene expression. These modulating agents have potential as therapeutic agents for treating type 1 and type 2 diabetes mellitus, endocrine and non-endocrine hypoplasia, hypertrophy, adenoma, neoplasia and nesidioblastosis

ACCESSION NUMBER: ACF05863 DNA DGENE

TITLE: New isolated **INGAP** nucleic acid, useful for diagnosing and treating disorders associated with reduced islet cell function and/or aberrant expression or activity of **INGAP**, such as type II diabetes mellitus.

INVENTOR: Taylor-Fishwick D; Vinik A I

PATENT ASSIGNEE: (GMPE-N)GMP ENDOTHERAPEUTICS INC.

PATENT INFO: WO 2003060096 A2 20030724 118p

APPLICATION INFO: WO 2003-US707 20030110

PRIORITY INFO: US 2002-346898P 20020111

US 2002-361073P 20020301

US 2002-388315P 20020614

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2003-598524 [56]

DESCRIPTION: Hamster **INGAP** gene PCR primer INGEN 1_3.